Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. (NASDAQ: CELU) is a regenerative and aging-related cellular medicine company whose news flow reflects developments across placental-derived biomaterial products, cell therapies, financing, and regulatory milestones. As a Nasdaq-listed issuer, Celularity regularly reports corporate updates, clinical data, partnerships, and capital markets transactions that are relevant to investors and observers of the regenerative medicine and longevity sectors.
News about Celularity often covers its advanced biomaterial products and wound care franchise, including updates on Biovance and Biovance 3L human amniotic membrane allografts and related reimbursement and coverage policies. The company has commented on Centers for Medicare & Medicaid Services decisions affecting skin substitute products and has highlighted real-world evidence from clinical use of its wound care products. These items can influence perceptions of the company’s commercial trajectory in chronic wound management.
Another key category of Celularity news involves its placenta-derived cell therapy programs, such as PDA-002. The company has announced peer-reviewed Phase 2 clinical trial results in diabetic foot ulcers complicated by peripheral artery disease and has discussed how state-level laws, particularly in Florida, may enable physician-directed use of certain stem cell therapies in orthopedics, wound care, and pain management. Such updates provide insight into the clinical and regulatory landscape for its investigational products.
Celularity’s press releases also address strategic partnerships and corporate structure. Examples include collaborations with Fountain Life in longevity-focused centers and with DefEYE, Inc. in ophthalmic biologics, as well as internal restructuring into distinct operating subsidiaries. In addition, the company reports on financings, debt restructuring, Nasdaq listing rule matters, and preferred stock or warrant issuances. For readers tracking CELU, this news page aggregates these developments so they can follow how Celularity’s placental-derived platform, commercial units, and capital structure evolve over time.
Celularity Inc. (NASDAQ: CELU) is advancing its focus on cellular therapies for cancer and degenerative diseases. CEO Robert J. Hariri spoke at the Future Investment Initiative in Riyadh, highlighting the company's commitment to global expansion, particularly in Saudi Arabia. Celularity is leveraging placental-derived cell technology to develop therapies aimed at enhancing human health and performance. The firm targets age-related conditions and is exploring collaborations within Saudi Vision 2030 for healthcare innovation across the MENA region.
Imugene Limited and Celularity Inc. have presented preclinical data on their collaboration at the Annual Meeting of the Society for Immunotherapy of Cancer. The study showcases the efficacy of Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with Celularity’s CYCART-19 T cells against triple-negative breast cancer. Notably, the results indicate enhanced tumor regression and immune activation. The presentation aims to further clinical development and highlights the potential of this combination therapy in treating solid tumors.
Celularity Inc. (Nasdaq: CELU) reported significant advancements in its clinical trials and management structure. The company announced the first patient treated in Phase 1/2a trial for CYNK-101 in advanced HER2 positive gastric cancer. Financially, Celularity improved its balance sheet with $150 million financing. In Q3 2022, it reported a net income of $4.8 million, a decline from $49.9 million in the prior year, while reducing net losses to $10.2 million YTD. Research expenses rose by $3.7 million year-over-year, highlighting ongoing investment in development.
Celularity Inc. (Nasdaq: CELU) announced the presentation of preclinical data on its CYNK-101, a placental-derived NK cell therapy, at the 37th Annual Meeting of The Society for Immunotherapy of Cancer in Boston. The study highlights CYNK-101's combination with avelumab, demonstrating enhanced antibody-dependent cellular cytotoxicity (ADCC) against PD-L1+ solid tumors, including non-small cell lung cancer and triple-negative breast cancer. The poster will be presented on November 11, 2022, showcasing promising next steps for this innovative cancer therapy.
Celularity Inc. (Nasdaq: CELU) announced the promotion of John R. Haines to Senior Executive Vice President and Chief Administrative Officer, and Brad Glover, Ph.D., to Executive Vice President and Chief Operating Officer. Both will serve on a newly established Executive Committee led by CEO Robert J. Hariri. Haines will spearhead international expansion strategies and oversee business operations, while Glover will manage corporate strategic planning and operational decision-making. These leadership changes aim to enhance Celularity's growth in cell therapy and biomaterials.
Celularity Inc. has appointed Adrian Kilcoyne, M.D., M.P.H., M.B.A. as Executive Vice President and Chief Medical Officer. With over 15 years in oncology and immunology, he has a strong background in advancing clinical programs. His role will be crucial in pushing Celularity’s clinical pipeline towards FDA approval. The company is currently conducting three Phase 1 studies targeting acute myeloid leukemia, glioblastoma multiforme, and gastric cancer, alongside an IND-pending program for B-cell malignancies. Kilcoyne’s expertise is expected to accelerate key clinical milestones.
Celularity Inc. (Nasdaq: CELU), a clinical-stage biotechnology firm, announced that its Founder and CEO, Robert Hariri, will present at the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 11 a.m. ET. The presentation will be accessible via a live webcast on Celularity's investor relations page, with a replay available for 30 days post-event. Celularity focuses on developing allogeneic cell therapies derived from the placenta, targeting cancer and infectious diseases. The company aims to provide effective, affordable therapies leveraging the unique biology of the placenta.
Celularity Inc. (Nasdaq: CELU) announced a study published in Frontiers in Immunology highlighting the antiviral properties of its placental-derived NK cells (CYNK-001) against influenza A virus (IAV). The research indicates that CYNK-001 targets IAV-infected cells, potentially benefiting patients with limited treatment options. Celularity's CYNK-001 is recognized as the first FDA-cleared immunotherapy for COVID-19 treatment. Annual costs associated with influenza in the U.S. are estimated at USD 10.4 billion, underscoring the need for effective antiviral therapies.
Celularity Inc. (Nasdaq: CELU) announced a Pre-Paid Advance Agreement with YA II PN, LTD for up to $150 million over 18 months. Each advance can be as much as $40 million, issued at a 2% discount with a 6% interest rate. If an outstanding balance exists, Celularity may need to sell shares at a price tied to a 135% or 95% of the VWAP, with a minimum price of $0.75. Proceeds will be used for working capital and to support R&D initiatives. The agreement is detailed in a shelf registration statement filed with the SEC.
Celularity Inc. (Nasdaq: CELU), a clinical-stage biotech firm, announced that CEO Robert Hariri will participate in investor conferences. He will engage in fireside chats at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 1:30 p.m. ET, and the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 12:20 p.m. ET. Live webcasts will be available on Celularity's website and archived for 30 days post-event.
Celularity focuses on developing placental-derived cell therapies for cancer and other diseases.
FAQ
What is the current stock price of Celularity (CELU)?
What is the market cap of Celularity (CELU)?
